NeoObs

Geneva, 26 April 2022 – A large study focusing on newborn babies with clinically diagnosed sepsis has revealed the impact of antibiotic resistance on neonatal sepsis, a major cause of death in newborns.

At the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), the Global Antibiotic Research and Development Partnership (GARDP) has released a second wave of findings from its study on the outcomes of more than 3,200 newborns with neonatal sepsis,

Ginevra, 26 Aprile 2022 – Un importante studio sui neonati ha rivelato l’impatto della resistenza agli antibiotici sulla sepsi neonatale, una delle principali cause di morte tra i neonati.

Al Congresso europeo di microbiologia clinica e malattie infettive (ECCMID), GARDP – un partenariato internazionale per la ricerca e lo sviluppo di antibiotici (Global Antibiotic Research and Development Partnership) – ha presentato una serie di risultati provenienti da uno studio condotto su oltre 3.200 neonati con sepsi neonatale,

Penta project manager Davide Bilardi, together with other NeoObs project partners, recently visited the neonatal units of the Santa Casa Hospital in São Paolo and the Clinical Research Unit of University of São Paolo in Ribeirao Preto. The visit occurred in the last week of January and was an opportunity to strengthen the relationship with new partner sites involved in the activities of this study. NeoObs is an observational study focused on understanding sepsis in newborns and current antibiotic prescribing practices.